Axsome Therapeutics: 660% Gain Over Five Years, Analysts Target 35% Upside
Axsome Therapeutics (AXSM) has surged roughly 660% in the last five years, and analysts now see a 35% upside to its current price, with a target of $285.42.
Key Takeaways
- Shares climbed about 660% over the past five years.
- Analysts average price target is $285.42, implying a 35% upside.
- Q2 revenue rose 46% YoY to $218.4 million, driven by Auvelity sales of $180.3 million.
- Auvelity received a label expansion for Alzheimer’s disease agitation, enlarging its market.
- Upcoming Phase 3 trials for AXS‑14 (fibromyalgia) and AXS‑20 (schizophrenia) and potential approval for AXS‑12 (narcolepsy) could add new products.
| Metric | Value | Why it matters |
|---|---|---|
| 5‑year share growth | ~660% | Shows sustained outperformance versus broader markets. |
| Q2 revenue | $218.4 million | Indicates strong sales momentum. |
| Auvelity sales | $180.3 million | Largest contributor to revenue growth. |
| Price target | $285.42 | Reflects 35% upside expectation. |
| Pipeline depth | Multiple late‑stage trials | Provides resilience against setbacks. |
What Is Axsome Therapeutics?
Axsome Therapeutics is a specialty pharmaceutical company that develops treatments for central nervous system disorders. Its portfolio includes Auvelity for depression, Sunosi for daytime sleepiness in narcolepsy, and Symbravo for migraine. The company has recently expanded Auvelity’s indication to Alzheimer’s disease agitation, opening a new patient segment.
Financial Momentum: Q2 Results and Revenue Drivers
In the second quarter, Axsome reported revenue that rose 46% year over year to $218.4 million. Auvelity alone generated $180.3 million in sales, a 51% increase from the same period last year. The label expansion for Alzheimer’s disease agitation is expected to add millions of patients to Auvelity’s addressable market, potentially boosting future sales.
Pipeline and Upcoming Catalysts
Axsome is advancing several late‑stage programs. A Phase 3 trial of AXS‑14 for fibromyalgia is underway, while Phase 3 studies for AXS‑20 in schizophrenia are being prepared. The company also anticipates approval for AXS‑12, a narcolepsy treatment, by May of next year. Successful outcomes from these programs could introduce new revenue streams and further diversify the company’s product lineup.
Market Outlook and Analyst Sentiment
Wall Street remains optimistic. Yahoo! Finance lists an average price target of $285.42 for AXSM, implying a 35% upside from its current level. Despite a recent 3.03% decline in the stock’s price, analysts view the long‑term trajectory favorably, citing robust growth drivers and a deep pipeline.
Risk Factors and Long‑Term Resilience
Like any biotech, Axsome faces uncertainties. Regulatory setbacks or broader equity market volatility could temporarily depress the stock. However, the company’s pipeline depth—multiple Phase 3 trials and potential approvals—provides a buffer. Since 2021, Axsome has weathered headwinds and still outperformed broader equities, suggesting a capacity to absorb short‑term shocks.
Strategic Positioning Through 2031
Even if only half of its ongoing late‑stage trials succeed, Axsome could still launch at least a couple of new products or label expansions by the end of the decade. The company’s Phase 2 programs are also progressing, and revenue is expected to grow steadily as it expands into large markets such as Alzheimer’s disease agitation. Analysts believe Axsome is well‑positioned to deliver competitive returns through 2031, even if it does not reach the Street’s price target within a year.
Why It Matters
For investors looking to add a high‑growth biotech to their portfolio, Axsome offers a compelling blend of proven revenue growth and a robust pipeline. The 35% upside estimate reflects both current performance and the potential impact of upcoming clinical milestones. However, the inherent risks of drug development and market volatility mean that the stock’s trajectory could shift in the short term. Understanding these dynamics helps you gauge whether Axsome aligns with your risk tolerance and long‑term investment goals.
Frequently Asked Questions
What is the current price of Axsome Therapeutics?
As of the latest trading session, Axsome’s share price is down 3.03% from the previous close. The exact price is not specified in the source data.
How much has the stock grown over the last five years?
The stock has climbed about 660% over the past five years, indicating strong long‑term performance.
What are the main drivers behind the 35% upside estimate?
Analysts base the 35% upside on the average price target of $285.42, which is 35% higher than the current market level. This estimate incorporates revenue growth, Auvelity’s label expansion, and the potential success of upcoming trials.
What upcoming clinical trials could impact the stock?
Key trials include Phase 3 studies for AXS‑14 (fibromyalgia) and AXS‑20 (schizophrenia), as well as a potential approval for AXS‑12 (narcolepsy) by May next year.
How does Axsome's performance compare to broader equities?
Since 2021, Axsome has faced headwinds but has still outperformed broader equities, demonstrating resilience in a challenging market environment.
Bottom Line
Axsome Therapeutics has delivered impressive growth and maintains a deep pipeline that could drive further upside. Analysts see a 35% potential gain over the next year, supported by strong Q2 results and upcoming clinical milestones. While short‑term volatility and regulatory risks remain, the company’s track record and strategic positioning suggest it could offer competitive returns through 2031. Whether Axsome is a fit for your portfolio depends on your appetite for biotech risk and your long‑term horizon.
This is educational information, not personalized financial advice.
Reporting based on: original source.